Cargando…
Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities
BACKGROUND: The association between pulmonary involvement and microscopic polyangiitis (MPA) has been increasingly recognized in recent years. Whether interstitial lung disease (ILD) and bronchiectasis (BE) are disease manifestations of MPA, preexisting comorbidities or important complications remai...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134949/ https://www.ncbi.nlm.nih.gov/pubmed/37126372 http://dx.doi.org/10.1080/07853890.2023.2204449 |
_version_ | 1785031859606913024 |
---|---|
author | Zhang, Yun Ding, Qunli Lv, Chengna Ying, Yanan Cen, Zekai Zhou, Haijun Wu, Tingting |
author_facet | Zhang, Yun Ding, Qunli Lv, Chengna Ying, Yanan Cen, Zekai Zhou, Haijun Wu, Tingting |
author_sort | Zhang, Yun |
collection | PubMed |
description | BACKGROUND: The association between pulmonary involvement and microscopic polyangiitis (MPA) has been increasingly recognized in recent years. Whether interstitial lung disease (ILD) and bronchiectasis (BE) are disease manifestations of MPA, preexisting comorbidities or important complications remains unclear. The purpose of this study was to determine the clinical characteristics and prognosis of MPA with pulmonary involvement to further guide clinical management. METHODS: The data for 97 patients with a definitive diagnosis of MPA were retrospectively reviewed. The MPA diagnosis was based on the 2012 revised Chapel Hill Consensus Conference (CHCC) criteria. The baseline clinical information and laboratory parameters were collected and analysed at each patient’s initial diagnosis. RESULTS: Forty-seven out of the 97 (48.5%) patients who were diagnosed with MPA presented with pulmonary involvement, including 37 patients with ILD, 12 patients with BE and two patients with diffuse alveolar haemorrhage (DAH). ILD and BE antedated MPA in 56.76% and 75.00% of the patients, respectively. Compared with that in the MPA-BE group, the serum LDH level (222.86 ± 68.19 vs. 171.58 ± 31.43, p = .016) in the MPA-ILD group was significantly higher. In the multivariate Cox analysis, elevated serum creatinine (HR 4.08, confidence interval (CI) 1.38–12.05, p = .011) was an independent risk factor for shorter survival in MPA patients with pulmonary involvement, and treatment with glucocorticoid pulse cyclophosphamide therapy (HR 0.095, 95% CI 0.019–0.47, p = .004) was independently associated with prolonged survival. Among the patients in the MPA-ILD group, acute exacerbations of ILD (HR 4.55 CI 1.16–17.86, p = .029) and elevated serum creatinine (HR 4.95, CI 1.39–17.54, p = .014) were independently associated with a poor prognosis, and treatment with glucocorticoids (HR 0.057, 95% CI 0.012–0.28, p < .001) was independently associated with significant prolongation of survival. CONCLUSIONS: Patients with MPA have a high prevalence of pulmonary involvement, and ILD is the most common subtype of MPA. ILD and BE can be considered preexisting comorbidities of MPA. Elevated serum creatinine was associated with shorter survival. However, remission induction regimens with glucocorticoids and/or immunosuppressants may improve this outcome. |
format | Online Article Text |
id | pubmed-10134949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-101349492023-04-28 Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities Zhang, Yun Ding, Qunli Lv, Chengna Ying, Yanan Cen, Zekai Zhou, Haijun Wu, Tingting Ann Med Pulmonary Medicine BACKGROUND: The association between pulmonary involvement and microscopic polyangiitis (MPA) has been increasingly recognized in recent years. Whether interstitial lung disease (ILD) and bronchiectasis (BE) are disease manifestations of MPA, preexisting comorbidities or important complications remains unclear. The purpose of this study was to determine the clinical characteristics and prognosis of MPA with pulmonary involvement to further guide clinical management. METHODS: The data for 97 patients with a definitive diagnosis of MPA were retrospectively reviewed. The MPA diagnosis was based on the 2012 revised Chapel Hill Consensus Conference (CHCC) criteria. The baseline clinical information and laboratory parameters were collected and analysed at each patient’s initial diagnosis. RESULTS: Forty-seven out of the 97 (48.5%) patients who were diagnosed with MPA presented with pulmonary involvement, including 37 patients with ILD, 12 patients with BE and two patients with diffuse alveolar haemorrhage (DAH). ILD and BE antedated MPA in 56.76% and 75.00% of the patients, respectively. Compared with that in the MPA-BE group, the serum LDH level (222.86 ± 68.19 vs. 171.58 ± 31.43, p = .016) in the MPA-ILD group was significantly higher. In the multivariate Cox analysis, elevated serum creatinine (HR 4.08, confidence interval (CI) 1.38–12.05, p = .011) was an independent risk factor for shorter survival in MPA patients with pulmonary involvement, and treatment with glucocorticoid pulse cyclophosphamide therapy (HR 0.095, 95% CI 0.019–0.47, p = .004) was independently associated with prolonged survival. Among the patients in the MPA-ILD group, acute exacerbations of ILD (HR 4.55 CI 1.16–17.86, p = .029) and elevated serum creatinine (HR 4.95, CI 1.39–17.54, p = .014) were independently associated with a poor prognosis, and treatment with glucocorticoids (HR 0.057, 95% CI 0.012–0.28, p < .001) was independently associated with significant prolongation of survival. CONCLUSIONS: Patients with MPA have a high prevalence of pulmonary involvement, and ILD is the most common subtype of MPA. ILD and BE can be considered preexisting comorbidities of MPA. Elevated serum creatinine was associated with shorter survival. However, remission induction regimens with glucocorticoids and/or immunosuppressants may improve this outcome. Taylor & Francis 2023-04-26 /pmc/articles/PMC10134949/ /pubmed/37126372 http://dx.doi.org/10.1080/07853890.2023.2204449 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Pulmonary Medicine Zhang, Yun Ding, Qunli Lv, Chengna Ying, Yanan Cen, Zekai Zhou, Haijun Wu, Tingting Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
title | Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
title_full | Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
title_fullStr | Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
title_full_unstemmed | Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
title_short | Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
title_sort | clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities |
topic | Pulmonary Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134949/ https://www.ncbi.nlm.nih.gov/pubmed/37126372 http://dx.doi.org/10.1080/07853890.2023.2204449 |
work_keys_str_mv | AT zhangyun clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities AT dingqunli clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities AT lvchengna clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities AT yingyanan clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities AT cenzekai clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities AT zhouhaijun clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities AT wutingting clinicalsignificanceofmicroscopicpolyangiitiswithinterstitiallungdiseaseandbronchiectasisprobabilityofpreexistingcomorbidities |